Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.582 EUR | -7.91% | -9.77% | +11.28% |
04-11 | Poxel: CDC falls below the 10% threshold | CF |
02-15 | Poxel S.A. Reports Unaudited Revenue Results for the Fourth Quarter and Full Year Ended December 31, 2023 | CI |
Business Summary
TWYMEEG® (Imeglimine), Poxel's lead product and the first in its class of medicines, which targets mitochondrial dysfunction, has been marketed in Japan for the treatment of type 2 diabetes.
For the treatment of NASH, the PXL065 met its primary endpoint in a streamlined Phase II trial, and PXL770 has completed a Phase IIa proof-of-concept study by reaching its objectives. In adrenoleukodystrophy (ALD), a rare inherited metabolic disease, the company intends to initiate Phase IIa proof-of-concept studies with the PXL065 and the PXL770 in patients with adrenomyeloneuropathy (AMN).
Sales per Business
EUR in Million | 2021 | Weight | 2022 | Weight | Delta |
---|---|---|---|---|---|
Innovative Treatments for Chronic Serious Disease
100.0
%
| 13 | 100.0 % | 1 | 100.0 % | -94.97% |
Sales per region
EUR in Million | 2021 | Weight | 2022 | Weight | Delta |
---|---|---|---|---|---|
France
100.0
%
| 13 | 100.0 % | 1 | 100.0 % | -94.97% |
Managers
Managers | Title | Age | Since |
---|---|---|---|
Founder | 61 | 05/03/09 | |
Sebastien Bolze
FOU | Founder | - | 05/03/09 |
Founder | - | 05/03/09 | |
Thomas Kuhn
FOU | Founder | 50 | 05/03/09 |
Sylvie Bertrand
HRO | Human Resources Officer | - | 31/12/20 |
Quentin Durand
LAW | General Counsel | - | 31/08/19 |
Members of the board
Members of the board | Title | Age | Since |
---|---|---|---|
Richard Kender
BRD | Director/Board Member | 68 | 11/03/15 |
Pascale Boissel
BRD | Director/Board Member | 57 | 04/03/15 |
Thomas Kuhn
FOU | Founder | 50 | 05/03/09 |
Chairman | 66 | 31/12/11 |
Share class
Vote | Quantity | Free-Float | Company-owned shares | Total Float | |
---|---|---|---|---|---|
Stock A | 1 | 34,252,646 | 34,106,683 ( 99.57 %) | 0 | 99.57 % |
Company contact information
Sector
1st Jan change | Capi. | |
---|---|---|
+9.42% | 115B | |
+11.84% | 106B | |
-1.05% | 21.96B | |
-14.15% | 21.87B | |
-5.29% | 19.21B | |
-4.16% | 18.08B | |
-38.29% | 17.71B | |
+7.99% | 14.32B | |
+36.24% | 12.42B |
- Stock Market
- Equities
- POXEL Stock
- 7PO Stock
- Company Poxel